Tuesday, July 12, 2011

Middle-income countries hurt in Gilead HIV drug deals, groups say

You can’t please everyone — that’s what the folks at Gilead Sciences Inc. must be muttering after announcing deals Tuesday morning that expand access to their life-saving HIV treatments in poor countries.
Good, say the international humanitarian organization Doctors Without Borders and Oxfam, but not good enough.

No comments:

Post a Comment